Serum markers as predictors of esophageal squamous dysplasia and early cancer

Anticancer Research

Volumn 24, Issue 5 B, 2004, Pages 3245-3249

  Chen, Wen ^a   Abnet, Christian C ^b,c   Wei, Wen Qiang ^a   Roth, Mark J ^b   Lu, Ning ^a   Taylor, Philip R ^b   Pan, Qin Jing ^a   Luo, Xian Mao ^a   Dawsey, Sanford M ^b   Qiao, You Lin ^a  

^a CANCER HOSPITAL   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Cancer Prevention Studies Branch   (United States)

Author keywords

Dysplasia; Esophagus; MMP 9

Indexed keywords

AUTOANTIBODY; COPPER ZINC SUPEROXIDE DISMUTASE; GELATINASE B; INTERLEUKIN 2 RECEPTOR; LUGOL; PROTEIN P53; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER;

ADULT; ARTICLE; BLOOD LEVEL; CANCER SCREENING; CHINA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DYSPLASIA; EARLY CANCER; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; ESOPHAGUS DISEASE; ESOPHAGUS DYSPLASIA; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; STAINING;

ADULT; AGED; AUTOANTIBODIES; BLOOD PROTEINS; CARCINOMA, SQUAMOUS CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PRECANCEROUS CONDITIONS; RECEPTORS, INTERLEUKIN-2; SUPEROXIDE DISMUTASE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 6344261760     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Parkin DM, Bray FI and Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 37: S4-66, 2001.
2. Dawsey SM, Lewin KJ, Wang GQ, Liu FS, Nieberg RK, Yu Y, Li JY, Blot WJ, Li B and Taylor PR: Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. A prospective follow-up study from Linxian, China. Cancer 74: 1686-1692, 1994.
3. Ke L: Mortality and incidence trends from esophagus cancer in selected geographic areas of China circa 1970-90. Int J Cancer 102: 271-274, 2002.
4. Roth MJ, Liu SF, Dawsey SM, Zhou B, Copeland C, Wang GQ, Solomon D, Baker SG, Giffen CA and Taylor PR: Cytologic detection of esophageal squamous cell carcinoma and precursor lesions using balloon and sponge samplers in asymptomatic adults in Linxian, China. Cancer 80: 2047-2059, 1997.
5. Dawsey SM, Lewin KJ, Liu FS, Wang GQ and Shen Q: Esophageal morphology from Linxian, China. Squamous histologic findings in 754 patients. Cancer 73: 2027-2037, 1994.
6. Dawsey SM, Fleischer DE, Wang GQ, Zhou B, Kidwell JA, Lu N, Lewin KJ, Roth MJ, Tio TL and Taylor PR: Mucosal iodine staining improves endoscopic visualization of squamous dysplasia and squamous cell carcinoma of the esophagus in Linxian, China. Cancer 83: 220-231, 1998.
7. Kuropkat C, Plehn S, Herz U, Dunne AA, Renz H and Werner JA: Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer. Anticancer Res 22: 2221-2227, 2002.
8. Ylisirnio S, Hoyhtya M and Turpeenniemi-Hujanen T: Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Res 20: 1311-1316, 2000.
9. Ylisirnio S, Hoyhtya M, Makitaro R, Paaakko P, Risteli J, Kinnula VL, Turpeenniemi-Hujanen T and Jukkola A: Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 7: 1633-1637, 2001.
10. Janssen AM, Bosman CB, van Duijn W, Oostendorp-van de Ruit MM, Kubben FJ, Griffioen G, Lamers CB, van Krieken JH, van de Velde CJ and Verspaget HW: Superoxide dismutases in gastric and esophageal cancer and the prognostic impact in gastric cancer. Clin Cancer Res 6: 3183-3192, 2000.
11. Lin Y, Kikuchi S, Obata Y and Yagyu K: Serum copper / zinc superoxide dismutase (Cu / Zn SOD) and gastric cancer risk: a case-control study. Jpn J Cancer Res 93: 1071-1075, 2002.
12. Ralhan R, Arora S, Chattopadhyay TK, Shukla NK and Mathur M: Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer 85: 791-795, 2000.
13. Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, Kobayashi S and Ochiai T: Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 89: 1677-1683, 2000.
14. Shimada H, Ochiai T and Nomura F: Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 97: 682-689, 2003.
15. Sobti RC and Parashar K: A study on p53 protein and anti-p53 antibodies in the sera of patients with oesophageal cancer. Mutat Res 422: 271-277, 1998.
16. Jablonska E, Kozlowski M, Pietruska Z and Furman M: Soluble interleukin-2 receptor in serum of patients with esophageal carcinoma. Neoplasma 41: 315-318, 1994.
17. Oka M, Hazama S, Takahashi M, Yamamoto K, Abe T, Yoshino S, Hayashi H and Tangoku A: Relationship between serum levels of soluble interleukin-2 receptor and various disease parameters in patients with squamous cell carcinoma of the esophagus. Hepatogastroenterology 46: 2254-2259, 1999.
18. Wang LS, Chow KC, Li WY, Liu CC, Wu YC and Huang MH: Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma. Clin Cancer Res 6: 1445-1451, 2000.